We have a long history of making an impact in cardio-metabolic disorders, such as type 2 diabetes and cardiovascular disease.
Our focus on cardio-metabolic disorders research and treatments
We introduced our first cardiovascular therapy more than 60 years ago, and we continue our scientific efforts to deeply understand cardio-metabolic disorders. Cardio-metabolic disorders include cardiovascular diseases, such as heart failure and pulmonary arterial hypertension (PAH), and metabolic diseases, such as type 2 diabetes. They represent some of the most serious health challenges of the 21st century.
Advancements in cardio-metabolic research can make an impactful difference for patients, and there’s still much more work to be done. We strive for scientific excellence and innovation in all stages of research, from discovery through approval and afterwards.
The impact of cardio-metabolic disorders
We continue to build on our history of innovative therapies in cardiovascular disease to help increase our understanding and help patients around the world.
We work with experts throughout the cardiovascular community to advance research that can help improve the lives of patients with cardiovascular risk.
We're proud of our research team that is committed to helping people with type 2 diabetes.
Pulmonary arterial hypertension (PAH)
We're focused on advancing research in the field of PAH, a rare, progressive and life-threatening blood vessel disorder in which the pulmonary arteries (blood vessels that carry blood from the right side of the heart into the lungs) become thickened and narrowed. As a result, the right side of the heart needs to work harder to pump blood into the lungs. This additional stress can cause strain on the heart because it's not able to pump enough blood into the lungs to meet the requirements of the body.
Programs that make a difference
Bridging the Gap
To help address the growing challenge of diabetes, our company's Foundation established Bridging the Gap: Reducing Disparities in Diabetes Care. This initiative aims to improve access to high-quality diabetes care and reduce disparities in health outcomes among vulnerable and underserved populations with type 2 diabetes in the U.S.